These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 28482702

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M, Coiffier B, Kwon HC, Yoon SW.
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [Abstract] [Full Text] [Related]

  • 3. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS, Coiffier B, Kwon HC, Kim S.
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
    Kim WS, Ogura M, Kwon HC, Choi D.
    Future Oncol; 2017 May; 13(15s):17-29. PubMed ID: 28482701
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M.
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [Abstract] [Full Text] [Related]

  • 11. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I, Ewesuedo R, Lula S, Zacharchuk C.
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rituximab biosimilars.
    Vital EM, Kay J, Emery P.
    Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
    Coiffier B.
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J, Kudrin A.
    Immunotherapy; 2015 Sep; 7(2):73-87. PubMed ID: 25713985
    [Abstract] [Full Text] [Related]

  • 19. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR, La-Fargue CJ, Tewari KS.
    Recent Pat Biotechnol; 2018 Sep; 12(2):101-112. PubMed ID: 29173192
    [Abstract] [Full Text] [Related]

  • 20. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U, Hong S, Oh C, Taylor P.
    Expert Rev Clin Immunol; 2015 Sep; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.